Antineoplastic effects of siRNA against TMPRSS2-ERG junction oncogene in prostate cancer

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Urbinati, Giorgia ^a,b   Ali, Hafiz Muhammad ^a,b   Rousseau, Quentin ^a,b,c   Chapuis, Hubert ^d   Desmaële, Didier ^d   Couvreur, Patrick ^d   Massaad Massade, Liliane ^a,b  

^a France   (France)

^b CNRS   (France)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UNIV PARIS SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; KI 67 ANTIGEN; MESSENGER RNA; NANOPARTICLE; ONCOPROTEIN; SMALL INTERFERING RNA; SQUALENE; TRANSCRIPTION FACTOR ERG; WATER; ADRA2A PROTEIN, HUMAN; ALPHA 2 ADRENERGIC RECEPTOR; ANTINEOPLASTIC AGENT; DRUG CARRIER; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CONJUGATION; DRUG TARGETING; FUSION GENE; GENE CONTROL; GENE SILENCING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; SCID MOUSE; TMPRSS2 ERG JUNCTION ONCOGENE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; MALE; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASPASE 3; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG CARRIERS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; MALE; MICE; MICE, SCID; NANOPARTICLES; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; RECEPTORS, ADRENERGIC, ALPHA-2; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SQUALENE; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928784145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125277     Document Type: Article

References (38)

1. Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephrourol Mon. 2013; 5(3):792-800. Epub 2013/11/28. doi: 10.5812/numonthly.9430 PMID: 24282788; PubMed Central PMCID: PMC3830904.
2. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008; 8(7):497-511. Epub 2008/06/20. nrc2402 [pii] doi: 10.1038/nrc2402 PMID: 18563191; PubMed Central PMCID: PMC2711688.
3. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, et al. Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. Eur J Cancer. 2014. Epub 2014/04/08. S0959-8049(14)00253-6 [pii] doi: 10.1016/j.ejca.2014.03.010 PMID: 24703899.
4. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-8. PMID: 16254181.
5. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008; 68(10):3584-90. Epub 2008/05/17. 68/10/3584 [pii] doi: 10.1158/0008-5472.CAN-07-6154 PMID: 18483239; PubMed Central PMCID: PMC2677168.
6. Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther. 2007; 6(1):40-5. Epub 2006/12/19. doi: 3489 [pii]. PMID: 17172822.
7. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology. 2007; 20(5):538-44. doi: 10.1038/modpathol.3800769 PMID: 17334343
8. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008; 27(3):253-63. Epub 2007/07/20. 1210640 [pii] doi: 10.1038/sj.onc.1210640 PMID: 17637754; PubMed Central PMCID: PMC2646890.
9. Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A, et al. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. Prostate. 2013; 73(9):905-12. Epub 2013/01/22. doi: 10.1002/pros.22636 PMID: 23334893; PubMed Central PMCID: PMC3677047.
10. Wu F, Ding S, Lu J. Truncated ERG proteins affect the aggressiveness of prostate cancer. Med Hypotheses. 2013; 80(4):490-3. Epub 2013/01/30. S0306-9877(12)00561-0 [pii] doi: 10.1016/j.mehy.2012.12.012 PMID: 23357671.
11. Leong. Over expression of truncated ERG from TMPRSS2-ERG fusion and prostate cancer development. Dovepress. 2009.
12. Wang J. Expression of Variant TMPRSS2/ERG Fusion Messenger RNAs Is Associated with Aggressive Prostate Cancer. Cancer Research. 2006; 66(17):8347-51. doi: 10.1158/0008-5472.can-06-1966 PMID: 16951141
13. Wang J, Cai Y, Yu W, Ren C, Spencer DM, Ittmann M. Pleiotropic Biological Activities of Alternatively Spliced TMPRSS2/ERG Fusion Gene Transcripts. Cancer Research. 2008; 68(20):8516-24. doi: 10.1158/0008-5472.can-08-1147 PMID: 18922926
14. White NM, Feng FY, Maher CA. Recurrent rearrangements in prostate cancer: causes and therapeutic potential. Curr Drug Targets. 2013; 14(4):450-9. Epub 2013/02/16. doi: CDT-EPUB-20130211-7 [pii]. PMID: 23410129; PubMed Central PMCID: PMC3733264.
15. Liu W, Ewing CM, Chang B- L, Li T, Sun J, Turner AR, et al. Multiple genomic alterations on 21q22 predict variousTMPRSS2/ERG fusion transcripts in human prostate cancers. Genes, Chromosomes and Cancer. 2007; 46(11):972-80. doi: 10.1002/gcc.20482 PMID: 17654723
16. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007; 26(18):2667-73. doi: 10.1038/sj.onc.1210070 PMID: 17043636
17. Ali HM, Urbinati G, Raouane M, Massaad-Massade L. Significance and applications of nanoparticles in siRNA delivery for cancer therapy. Expert Rev Clin Pharmacol. 2012; 5(4):403-12. Epub 2012/09/05. doi: 10.1586/ecp.12.33 PMID: 22943120.
18. Raouane M, Desmaele D, Urbinati G, Massaad-Massade L, Couvreur P. Lipid Conjugated Oligonucleotides: A Useful Strategy for Delivery. Bioconjug Chem. 2012. Epub 2012/03/01. doi: 10.1021/bc200422w PMID: 22372953.
19. Ali HM, Urbinati G, Chapuis H, Desmaele D, Bertrand JR, Couvreur P, et al. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. PLoS One. 2014; 9(4):e95964. Epub 2014/04/25. doi: 10.1371/journal.pone.0095964 [doi] PONE-D-13-52959 [pii]. PMID: 24759995.
20. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nature Biotechnology. 2004; 22(3):326-30. doi: 10.1038/nbt936 PMID: 14758366
21. Tuschl T. Expanding small RNA interference. Nat Biotechnol. 2002; 20(5):446-8. Epub 2002/05/01. doi: 10.1038/nbt0502-446 nbt0502-446 [pii]. PMID: 11981553.
22. Gilbert-Sirieix M, Ripoche H, Malvy C, Massaad-Massade L. Effects of silencing RET/PTC1 junction oncogene in human papillary thyroid carcinoma cells. Thyroid. 2010; 20(10):1053-65. Epub 2010/07/10. doi: 10.1089/thy.2010.0006 [doi]. PMID: 20615140.
23. Raouane M, Desmaele D, Gilbert-Sirieix M, Gueutin C, Zouhiri F, Bourgaux C, et al. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. J Med Chem. 2011; 54(12):4067-76. Epub 2011/05/13. doi: 10.1021/jm2000272 PMID: 21561161.
24. Korenchuk S, Lehr JE, L MC, Lee YG, Whitney S, Vessella R, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo. 2001; 15(2):163-8. Epub 2001/04/25. PMID: 11317522.
25. Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 2007; 21(16):2005-17. Epub 2007/08/19.21/16/2005 [pii] doi: 10.1101/gad.1564207 PMID: 17699749; PubMed Central PMCID: PMC1948856.
26. Hu XY, Xu YM, Chen XC, Ping H, Chen ZH, Zeng FQ. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. Apmis. 2006; 114(12):893-8. doi: 10.1111/j.1600-0463.2006.apm-271.x PMID: ISI:000242902800009.
27. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004; 4(10):793-805. Epub 2004/10/29. nrc1455 [pii] doi: 10.1038/nrc1455 PMID: 15510160.
28. Furlan A, Stagni V, Hussain A, Richelme S, Conti F, Prodosmo A, et al. Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ. 2011; 18(10):1608-16. doi: 10.1038/Cdd.2011.23 PMID: ISI:000294757800008.
29. Wang LG, Ni Y, Su BH, Mu XR, Shen HC, Du JJ. MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol. 2013; 42(3):957-62. doi: 10.3892/ijo.2013.1767 PMID: ISI:000314905700020.
30. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8(2):129-38. Epub 2009/01/31. nrd2742 [pii] doi: 10.1038/nrd2742 PMID: 19180106.
31. Reddy LH, Couvreur P. Squalene: A natural triterpene for use in disease management and therapy. Adv Drug Deliv Rev. 2009; 61(15):1412-26. Epub 2009/10/07. S0169-409X(09)00284-1 [pii] doi: 10.1016/j.addr.2009.09.005 PMID: 19804806.
32. Ali HM, Maksimenko A, Urbinati G, Chapuis H, Raouane M, Desmaele D, et al. Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol. Thyroid. 2014; 24(2):327-38. Epub 2013/07/28. doi: 10.1089/thy.2012.0544 PMID: 23885719.
33. Ali HM, Urbinati G, Chapuis H, Desmaële D, Bertrand J-R, Couvreur P, et al. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. PLoS One. 2014b; 9:e95964. doi: 10.1371/journal.pone.0095964 PMID: 24759995
34. Leus NG, Morselt HW, Zwiers PJ, Kowalski PS, Ruiters MH, Molema G, et al. VCAM-1 specific PEGylated SAINT-based lipoplexes deliver siRNA to activated endothelium in vivo but do not attenuate target gene expression. Int J Pharm. 2014. Epub 2014/04/22. S0378-5173(14)00277-4 [pii] doi: 10.1016/j.ijpharm.2014.04.041 PMID: 24746643.
35. Leus NG, Talman EG, Ramana P, Kowalski PS, Woudenberg-Vrenken TE, Ruiters MH, et al. Effective siRNA delivery to inflamed primary vascular endothelial cells by anti-E-selectin and anti-VCAM-1 PEGylated SAINT-based lipoplexes. Int J Pharm. 2014; 459(1-2):40-50. Epub 2013/11/19. S0378-5173(13)00976-9 [pii] doi: 10.1016/j.ijpharm.2013.11.008 PMID: 24239833.
36. Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, et al. TMPRSS2-ERG-Mediated Feed-Forward Regulation of Wild-Type ERG in Human Prostate Cancers. Cancer Research. 2011; 71(16):5387-92. doi: 10.1158/0008-5472.can-11-0876 PMID: 21676887
37. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008; 27(40):5348-53. Epub 2008/06/11. onc2008183 [pii] doi: 10.1038/onc.2008.183 PMID: 18542058.
38. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, et al. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012; 18(24):6648-57. Epub 2012/10/12. 1078-0432.CCR-12-2715 [pii] doi: 10.1158/1078-0432.CCR-12-2715 [doi]. PMID: 23052253.